Exhibit 99.1

ACURA PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

	(audited)		(audited)
	December 31,		December 31,
	2021		2020
Assets – current	$	372	$	1,179
Property, plant and equipment, net		438		484
Other assets		50		73
Total assets	$	860	$	1,736
Other liabilities - current	$	515	$	680
Loan under CARES Act - current		-		164
Accrued interest to related party – current		-		678
Convertible debt to related party – current		-		6,000
Loan under CARES Act – non current		-		105
Promissory note to related party – non current		150		-
Other liabilities – non current		17		-
Stockholders' equity (deficit)		178		(5,891	)
Total liabilities and stockholders' equity (deficit)	$	860	$	1,736

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

	(unaudited)						(audited)
	Three Months Ended December 31,						Twelve Months Ended December 31,
	2021			2020			2021			2020
Revenues:
Royalties	$	30		$	28		$	132		$	109
Collaboration from related party		6			90			31			238
License fees from related party		-			600			1,400			3,000
Product sales		-			-			-			223
Total revenues		36			718			1,563			3,570
Operating expenses:
Research and development		344			430			1,524			1,781
General and administrative		(71	)		419			1,253			2,547
Total operating expenses		273			849			2,777			4,328
Operating loss		(237	)		(131	)		(1,214	)		(758	)
Gain on forgiveness of loans under CARES Act		266			-			535			-
Interest expense to related party		-			(112	)		(200	)		(450	)
Income (loss) before provision for income taxes		29			(243	)		(879	)		(1,208	)
Provision for income taxes		-			-			-			-
Net income (loss)	$	29		$	(243	)	$	(879	)	$	(1,208	)
Net loss per share:
Basic	$	(0.00	)	$	(0.01	)	$	(0.02	)	$	(0.04	)
Diluted	$	(0.00	)	$	(0.01	)	$	(0.02	)	$	(0.04	)
Weighted average number of shares outstanding:
Basic		75,604			32,319			56,801			32,320
Diluted		75,604			32,319			56,801			32,320